Ayvakit fails to meet primary endpoint in Phase III VOYAGER trial versus regorafenib for gastrointestinal stromal tumor.- Blueprint Medicines Corpn.
Blueprint Medicines Corporation , a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced top-line results from the Phase III VOYAGER clinical trial… read more.